Osteoclast-specifc cathepsin K deletion stimulates S1P-dependent bone formation

Journal of Clinical Investigation

Volumn 123, Issue 2, 2013, Pages 666-681

  Lotinun, Sutada ^a   Kiviranta, Riku ^a,b   Matsubara, Takuma ^a   Alzate, Jorge A ^a   Neff, Lynn ^a   Lüth, Anja ^c   Koskivirta, Ilpo ^b   Kleuser, Burkhard ^c   Vacher, Jean ^d   Vuorio, Eero ^b   Horne, William C ^a   Baron, Roland ^a,e  

^a HARVARD SCHOOL OF DENTAL MEDICINE   (United States)

^b UNIVERSITY OF TURKU   (Finland)

^c UNIVERSITY OF POTSDAM   (Germany)

^d CLIN RESEARCH INSTITUTE OF MONTREAL   (Canada)

^e MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALKALINE PHOSPHATASE; CATHEPSIN K; OSTEOCLAST DIFFERENTIATION FACTOR; SPHINGOSINE 1 PHOSPHATE; CTSK PROTEIN, MOUSE; DRUG DERIVATIVE; LYSOPHOSPHOLIPID; OSTEOPROTEGERIN; SPHINGOSINE; SPHINGOSINE 1-PHOSPHATE; TNFRSF11B PROTEIN, MOUSE; TNFSF11 PROTEIN, MOUSE;

ALLELE; ANIMAL CELL; ANIMAL CELL CULTURE; ANIMAL TISSUE; ARTICLE; BONE DENSITY; BONE MASS; CONTROLLED STUDY; DENSITY; GENE DELETION; MOUSE; NONHUMAN; OSSIFICATION; OSTEOBLAST; OSTEOCLAST; OSTEOLYSIS; POSITIVE FEEDBACK; PRIORITY JOURNAL; ANIMAL; BIOLOGICAL MODEL; BONE DEVELOPMENT; BONE MARROW CELL; C57BL MOUSE; CELL DIFFERENTIATION; CYTOLOGY; DRUG ANTAGONISM; ENZYMOLOGY; FEEDBACK SYSTEM; FEMALE; GENETICS; MALE; METABOLISM; MOUSE MUTANT; PATHOLOGY; PHYSIOLOGY;

ANIMALS; BONE MARROW CELLS; BONE RESORPTION; CATHEPSIN K; CELL DIFFERENTIATION; FEEDBACK, PHYSIOLOGICAL; FEMALE; LYSOPHOSPHOLIPIDS; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MODELS, BIOLOGICAL; OSTEOBLASTS; OSTEOCLASTS; OSTEOGENESIS; OSTEOPROTEGERIN; RANK LIGAND; SPHINGOSINE;

MLCS; MLOWN;

EID: 84873401233     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI64840     Document Type: Article

References (54)

1. Nyman JS, Yeh OC, Hazelwood SJ, Martin RB. A theoretical analysis of long-term bisphosphonate effects on trabecular bone volume and microdamage. Bone. 2004;35(1):296-305.
2. Bone HG, Schurr W. Intravenous bisphosphonate therapy for osteoporosis: where do we stand? Curr Osteoporos Rep. 2004;2(1):24-30.
3. Khan AA, et al. Bisphosphonate associated osteonecrosis of the jaw. J Rheumatol. 2009;36(3):478-490.
4. Koh JS, Goh SK, Png MA, Kwek EB, Howe TS. Femoral cortical stress lesions in long-term bisphosphonate therapy: a herald of impending fracture? J Orthop Trauma. 2010;24(2):75-81.
5. Carvalho NN, Voss LA, Almeida MO, Salgado CL, Bandeira F. Atypical femoral fractures during prolonged use of bisphosphonates: short-term responses to strontium ranelate and teriparatide. J Clin Endocrinol Metab. 2011;96(9):2675-2680.
6. Black DM, et al. The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis. N Engl J Med. 2003;349(13):1207-1215.
7. Dougall WC, et al. RANK is essential for osteoclast and lymph node development. Genes Dev. 1999;13(18):2412-2424.
8. Douni E, et al. A RANKL G278R mutation causing osteopetrosis identifies a functional amino acid essential for trimer assembly in RANKL and TNF. Hum Mol Genet. 2012;21(4):784-798.
9. Schinke T, et al. Impaired gastric acidification negatively affects calcium homeostasis and bone mass. Nat Med. 2009;15(6):674-681.
10. Zenger S, et al. Proteolytic processing and polarized secretion of tartrate-resistant acid phosphatase is altered in a subpopulation of metaphyseal osteoclasts in cathepsin K-deficient mice. Bone. 2007;41(5):820-832.
11. Fuller K, et al. Cathepsin K inhibitors prevent matrix-derived growth factor degradation by human osteoclasts. Bone. 2008;42(1):200-211.
12. Gelb BD, Shi GP, Chapman HA, Desnick RJ. Pycnodysostosis, a lysosomal disease caused by cathepsin K deficiency. Science. 1996;273(5279):1236-1238.
13. Gelb BD, et al. Pycnodysostosis: refined linkage and radiation hybrid analyses reduce the critical region to 2 cM at 1q21 and map two candidate genes. Hum Genet. 1996;98(2):141-144.
14. Johnson MR, Polymeropoulos MH, Vos HL, Ortiz De Luna RI, Francomano CA. A nonsense mutation in the cathepsin K gene observed in a family with pycnodysostosis. Genome Res. 1996;6(11):1050-1055.
15. Saftig P, et al. Impaired osteoclastic bone resorption leads to osteopetrosis in cathepsin-K-deficient mice. Proc Natl Acad Sci U S A. 1998;95(23):13453-13458.
16. Gowen M, et al. Cathepsin K knockout mice develop osteopetrosis due to a deficit in matrix degradation but not demineralization. J Bone Miner Res. 1999;14(10):1654-1663.
17. Kiviranta R, et al. Impaired bone resorption in cathepsin K-deficient mice is partially compensated for by enhanced osteoclastogenesis and increased expression of other proteases via an increased RANKL/OPG ratio. Bone. 2005;36(1):159-172.
18. Pennypacker B, et al. Bone density, strength, and formation in adult cathepsin K (-/-) mice. Bone. 2009;44(2):199-207.
19. Li CY, et al. Mice lacking cathepsin K maintain bone remodeling but develop bone fragility despite high bone mass. J Bone Miner Res. 2006;21(6):865-875.
20. Ryu J, Kim HJ, Chang EJ, Huang H, Banno Y, Kim HH. Sphingosine 1-phosphate as a regulator of osteoclast differentiation and osteoclast-osteoblast coupling. EMBO J. 2006;25(24):5840-5851.
21. Aliprantis AO, et al. NFATc1 in mice represses osteoprotegerin during osteoclastogenesis and dissociates systemic osteopenia from inflammation in cherubism. J Clin Invest. 2008;118(11):3775-3789.
22. Beller DI, Springer TA, Schreiber RD. Anti-Mac-1 selectively inhibits the mouse and human type three complement receptor. J Exp Med. 1982;156(4):1000- 1009.
23. Shalhoub V, et al. Characterization of osteoclast precursors in human blood. Br J Haematol. 2000;111(2):501-512.
24. Ferron M, Vacher J. Targeted expression of Cre recombinase in macrophages and osteoclasts in transgenic mice. Genesis. 2005;41(3):138-145.
25. Ambrogini E, et al. FoxO-mediated defense against oxidative stress in osteoblasts is indispensable for skeletal homeostasis in mice. Cell Metab. 2010;11(2):136-146.
26. Leung P, Pickarski M, Zhuo Y, Masarachia PJ, Duong LT. The effects of the cathepsin K inhibitor odanacatib on osteoclastic bone resorption and vesicular trafficking. Bone. 2011;49(4):623-635.
27. Zhao H, Ito Y, Chappel J, Andrews NW, Teitelbaum SL, Ross FP. Synaptotagmin VII regulates bone remodeling by modulating osteoclast and osteoblast secretion. Dev Cell. 2008;14(6):914-925.
28. Davey RA, et al. Decreased body weight in young Osterix-Cre transgenic mice results in delayed cortical bone expansion and accrual. Transgenic Res. 2012;21(4):885-893.
29. Pederson L, Ruan M, Westendorf JJ, Khosla S, Oursler MJ. Regulation of bone formation by osteoclasts involves Wnt/BMP signaling and the chemokine sphingosine-1-phosphate. Proc Natl Acad Sci U S A. 2008;105(52):20764-20769.
30. Zhao C, et al. Bidirectional ephrinB2-EphB4 signaling controls bone homeostasis. Cell Metab. 2006;4(2):111-121.
31. Irie N, et al. Bidirectional signaling through ephrinA2-EphA2 enhances osteoclastogenesis and suppresses osteoblastogenesis. J Biol Chem. 2009;284(21):14637-14644.
32. Cusick T, et al. Odanacatib treatment increases hip bone mass and cortical thickness by preserving endocortical bone formation and stimulating periosteal bone formation in the ovariectomized adult rhesus monkey. J Bone Miner Res. 2012;27(3):524-537.
33. Jerome C, Missbach M, Gamse R. Balicatib, a cathepsin K inhibitor, stimulates periosteal bone formation in monkeys. Osteoporos Int. 2012;23(1):339-349.
34. Silva BC, Costa AG, Cusano NE, Kousteni S, Bilezikian JP. Catabolic and anabolic actions of parathyroid hormone on the skeleton. J Endocrinol Invest. 2011;34(10):801-810.
35. Ilmer M, Karow M, Geissler C, Jochum M, Neth P. Human osteoblast-derived factors induce early osteogenic markers in human mesenchymal stem cells. Tissue Eng Part A. 2009;15(9):2397-2409.
36. Podgorski I, et al. Bone marrow-derived cathepsin K cleaves SPARC in bone metastasis. Am J Pathol. 2009;175(3):1255-1269.
37. Mandelin J, et al. Human osteoblasts produce cathepsin K. Bone. 2006;38(6):769-777.
38. Tang Y, et al. TGF-β1-induced migration of bone mesenchymal stem cells couples bone resorption with formation. Nat Med. 2009;15(7):757-765.
39. Xiong J, Onal M, Jilka RL, Weinstein RS, Manolagas SC, O'Brien CA. Matrix-embedded cells control osteoclast formation. Nat Med. 2011;17(10):1235-1241.
40. Nakashima T, et al. Evidence for osteocyte regulation of bone homeostasis through RANKL expression. Nat Med. 2011;17(10):1231-1234.
41. Masarachia PJ, et al. Odanacatib reduces bone turnover and increases bone mass in the lumbar spine of skeletally mature ovariectomized rhesus monkeys. J Bone Miner Res. 2012;27(3):509-523.
42. Pennypacker BL, et al. Cathepsin K inhibitors prevent bone loss in estrogen-deficient rabbits. J Bone Miner Res. 2011;26(2):252-262.
43. Vasiljeva O, Reinheckel T, Peters C, Turk D, Turk V, Turk B. Emerging roles of cysteine cathepsins in disease and their potential as drug targets. Curr Pharm Des. 2007;13(4):387-403.
44. Costa AG, Cusano NE, Silva BC, Cremers S, Bilezikian JP. Cathepsin K: its skeletal actions and role as a therapeutic target in osteoporosis. Nat Rev Rheumatol. 2011;7(8):447-456.
45. Rantakokko J, Kiviranta R, Eerola R, Aro HT, Vuorio E. Complete genomic structure of the mouse cathepsin K gene (Ctsk) and its localization next to the Arnt gene on mouse chromosome 3. Matrix Biol. 1999;18(2):155-161.
46. Rantakokko J, Aro HT, Savontaus M, Vuorio E. Mouse cathepsin K: cDNA cloning and predominant expression of the gene in osteoclasts, and in some hypertrophying chondrocytes during mouse development. FEBS Lett. 1996;393(2-3):307-313.
47. Ruocco MG, et al. I{kappa}B kinase (IKK) {beta}, but not IKK{alpha}, is a critical mediator of osteoclast survival and is required for inflammation-induced bone loss. J Exp Med. 2005;201(10):1677-1687.
48. Parfitt AM, et al. Bone histomorphometry: standardization of nomenclature, symbols, and units. Report of the ASBMR Histomorphometry Nomenclature Committee. J Bone Miner Res. 1987;2:595-610.
49. Bouxsein ML, Boyd SK, Christiansen BA, Guldberg RE, Jepsen KJ, Muller R. Guidelines for assessment of bone microstructure in rodents using microcomputed tomography. J Bone Miner Res. 2010;25(7):1468-1486.
50. Bakker AD, Klein-Nulend J. Osteoblast isolation from murine calvaria and long bones. Methods Mol Biol. 2012;816:19-29.
51. Lotinun S, Evans GL, Turner RT, Oursler MJ. Deletion of membrane-bound steel factor results in osteopenia in mice. J Bone Miner Res. 2005;20(4):644-652.
52. Purev E, Neff L, Horne WC, Baron R. c-Cbl and Cbl-b act redundantly to protect osteoclasts from apoptosis and to displace HDAC6 from beta-tubulin, stabilizing microtubules and podosomes. Mol Biol Cell. 2009;20(18):4021-4030.
53. Ruwisch L, Schafer-Korting M, Kleuser B. An improved high-performance liquid chromatographic method for the determination of sphingosine-1-phosphate in complex biological materials. Naunyn Schmiedebergs Arch Pharmacol. 2001;363(3):358-363.
54. Yatomi Y, Ruan F, Ohta J, Welch RJ, Hakomori S, Igarashi Y. Quantitative measurement of sphingosine 1-phosphate in biological samples by acylation with radioactive acetic anhydride. Anal Biochem. 1995;230(2):315-320.